-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ranpirnase in Viral Conjunctivitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ranpirnase in Viral Conjunctivitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ranpirnase in Viral Conjunctivitis Drug Details: Ranpirnase (OKG-0301) is under development for...
-
Product Insights
Oskarshamn 3
Oskarshamn 3 is a nuclear project located in Kalmar, Sweden. The project is owned by Fortum Corp; Uniper SE and was developed by OKG Aktiebolag. The project came online in 1985. Empower your strategies with our Oskarshamn 3 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ranpirnase
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ranpirnase Drug Details Ranpirnase (OKG-0301) is under development for the treatment of Adenoviral conjuctivitis...
-
Product Insights
Viral Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines. The Viral conjunctivitis - drugs in development research report provides a comprehensive overview on the therapeutics under development for Viral conjunctivitis, complete with analysis by stage of development,...
-
Product Insights
Conjunctivitis Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Conjunctivitis Global Clinical Trials Review, H1, 2019" provides an overview of Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Conjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Analyst Opinions
Global Nuclear Decommissioning Market to Thrive Post 2025
Nuclear power rose into prominence since early 1950s mainly due to high energy density of nuclear fuel compared to conventional fossil fuel alternatives. It is estimated that a 1000 MW nuclear reactor annually requires around 30 tons of fresh fuel compared to coal power plant of equivalent capacity consuming over two and half million tons of coal to produce as much electricity. Presently there are over 450 operational nuclear power reactors in 30 countries all over the world contributing to...